Glaucoma, an optic neuropathy, is a major cause of vision loss worldwide, 1 with many cases of falls in women accounted for by severe glaucomatous visual field loss. POAG patients are initially treated with monotherapy; however, they often experience disease progression due to inadequate IOP reduction.
Despite the IOP-lowering effects of the monotherapies, patients often experience disease progression because the treatment fails to achieve the target IOP needed to limit progression. This failure may be due to either inadequate or a complete absence of IOP lowering. In patients who have either a small or even no reduction in IOP, switching to another monotherapy is recommended, while in patients who experience an expected but insufficient IOP lowering, switching to combination therapy is recommended. 10 The frequent need for the use of multiple medications to achieve sufficient IOP reduction is indicated by the Ocular Hypertension Treatment Study (OHTS). 9 The 60-month follow-up results from this study showed that around 40% of the patients had been prescribed at least two medications, with 9% taking at least three medications to meet their IOP goal. Although there seems to be a substantial need for combination therapy to achieve IOP lowering, patients may experience disease progression with multiple medications. In such cases, switching to other combination therapies may be considered. 9 Among the non-pharmacological therapies, laser trabeculoplasty or surgery may be considered when the mono-or combination therapies cannot achieve adequate reduction in IOP or are not tolerable to the patient. 
Possible Reasons for Glaucoma Progression on Combination Therapy
The combination therapeutic approach utilises either fixed or unfixed combinations of antiglaucoma medications, including drugs such as the prostaglandin analogues, β-blockers, carbonic anhydrases, etc.
While combination therapy may allow greater lowering of IOP than monotherapy, some patients still do not achieve the target IOP level.
Reasons cited for this include the lack of patient compliance to treatment and the presence of a 'wash-out effect'. Patient compliance is a major concern with multiple medications, with a survey showing that only 32% of patients on two medications (n=31)
were treatment-compliant versus 49% compliant patients on only one medication (n=41). 14 The study also found the rate of treatment compliance to be largely influenced by daily dose frequency, forgetfulness, inconvenience and unaffordability. Another major concern with combination therapy, particularly the unfixed 
Strategies to Improve Treatment Outcomes with Combination Therapy
When choosing a combination therapy, an individualised treatment approach is needed, as previously described. 9 This approach is based on the person's needs and circumstances, and is expected to improve patient compliance and the achievement of treatment outcomes. In addition, the European Glaucoma Society has suggested several factors or points to consider when selecting adjunctive therapies. 10 As a first step, only one medication should be 18 This was an observer-masked, active-controlled study in which patients with POAG (n=37) initially went medicine-free for six weeks and were then randomised to LTFC (QD) or latanoprost alone (QD), both dosed in the evening. After eight treatment weeks, patients were crossed over to the opposite treatment for a further eight weeks. The results showed that evening dosing of LTFC can result in an additional reduction in diurnal IOP of 1.5-2.9mmHg versus evening-dosed latanoprost alone (p<0.001). The degree of IOP reduction achieved with evening-dosed LTFC is much greater than that observed in studies where a morning dosing protocol for LTFC was used. In light of these findings, there is a shift towards an evening dosing schedule for LTFC. Nevertheless, the label for LTFC indicates that the dose can be given at any time of day, which allows therapy to be tailored to the patient's lifestyle and compliance.
Long-term efficacy data for LTFC are now available and show that this fixed combination can maintain its effectiveness over a long period. A recent study utilised data from the glaucoma database of the Glasgow Royal Infirmary, which is a real-life database. The data were from patients with POAG or OHT (n=59) who had insufficient IOP lowering with latanoprost monotherapy and were switched to LTFC therapy. 19 The results showed a significant mean additional reduction in IOP of 2.6mmHg with LTFC therapy versus latanoprost alone (p=0.002). The IOP reduction was from 21.4±3.5 to 18.8±4.2mmHg.
The long-term safety of LTFC has also been evaluated. A five-year open-label, phase IIIb, multicentre safety study accrued patients with either OAG or OHT (n=974) who required additional IOP lowering because monotherapy with β-blockers produced a partial and insufficient lowering of their IOP. 20 The interim three-year data (see Tailoring Pharmacological Therapy for the Progressing Primary Open-angle Glaucoma Patient 
Conclusions
Glaucoma progression leads to increasing treatment costs and reduced QoL. Reduction of IOP in glaucoma generally and specifically in POAG has proved to be the only viable strategy to limit disease progression and preserve visual function and QoL. Patients are initially treated with monotherapies but often experience disease progression, which is frequently a result of inadequate IOP lowering.
A combination therapeutic approach may be used to achieve the target IOP level in patients who do not achieve optimal IOP reduction. When considering the combination therapy, several factors need to be considered, particularly the use of as few medications as possible, thereby optimising patient compliance to treatment. The fixed combination preparations are highly preferable over the unfixed combinations, particularly because the former are associated with a higher compliance rate. Among the fixed combinations, LTFC (QD) has been most extensively studied and has been shown to be more effective than either of its individual components. It has IOP-lowering effects whether dosed in the morning or the evening, allowing effective treatment tailoring, although there is now a shift towards an evening dosing schedule.
Recent long-term data have shown LTFC to be effective, welltolerated and safe over a three-year treatment period in glaucoma patients who did not achieve the target IOP with monotherapy. n Glaucoma
